Basilea Pharmaceutica (LTS:0QNA) Change In Payables And Accrued Expense : CHF0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Change In Payables And Accrued Expense?

Basilea Pharmaceutica's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was CHF0.0 Mil. It means Basilea Pharmaceutica's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Basilea Pharmaceutica's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was CHF0.0 Mil. It means Basilea Pharmaceutica's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Basilea Pharmaceutica Change In Payables And Accrued Expense Historical Data

The historical data trend for Basilea Pharmaceutica's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Change In Payables And Accrued Expense Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Basilea Pharmaceutica Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.0 Mil.

Basilea Pharmaceutica Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (LTS:0QNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

BSLNz:UK BSLN:Switzerland

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines